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ABSTRACT
Access to affordable prescription drug products is a serious chal-
lenge faced by millions of Americans. More than 40% of Americans
take one or more prescription drugs; and a small, but increasing, num-
ber rely on drug importation to lower costs. Although some imported
drugs are legal, a far greater number are unregulated within the U.S.
drug distribution system and cannot be confirmed as safe and effec-
tive. Whether purchased online, from a storefront pharmacy, or dur-
ing travel to another country, foreign prescription drugs pose risks to
patient safety. The most serious risks include counterfeit potential,
quality assurance concerns, presence of untested ingredients, and is-
sues related to risk management and unsupervised use, labeling, lan-
guage, and lack of information. Import blitz exams confirm that a
wide variety of drug types entering the United States lack integrity in
manufacturing, packaging, labeling, storage, or distribution. The
FDA-initiated "Looks Can Be Deceiving" public information cam-
paign educates American consumers about the dangers of buying un-
approved foreign drugs, and current efforts to find and implement al-
ternatives to such drugs seem promising. The FDA has been active in
helping to accelerate access to generic drugs and exploring ways to
lower drug development and manufacturing costs. Furthermore, the
new Medicare prescription drug benefit will likely assist seniors in
purchasing affordable and safe medications. The policies and regula-
tions of the current, relatively "closed" U.S. drug distribution system
maximize the safety and effectiveness of the domestic drug supply and
serve as the model for systems around the world. Changes to the sys-
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tem, such as a legal commercial importation program, are not without
costs and would require careful scrutiny before implementation. A
personal importation system would likely result in an increased risk to
American drug consumers.
INTRODUCTION
Access to affordable prescription drug products is a serious chal-
lenge faced by millions of Americans. The increased use of such
products by an aging population and rising list prices over the past
several years have translated into increased spending by American
consumers. More than 40% of Americans take one or more prescrip-
tion drugs;1 and a small, but increasing, number rely on drug importa-
tion to lower costs.2 Although some imported drugs are legal and pose
little risk to patient safety, a far greater number are unregulated within
the U.S. drug distribution system and cannot be confirmed as safe and
effective.3
This essay presents a brief history of drug oversight in the United
States, addresses the nature and scope of drug importation, and fo-
cuses on the serious risks to patient health and well-being posed by the
importation of unapproved drugs. A discussion of alternatives to im-
ported drugs and the recent findings of the Health and Human Ser-
vices (HHS) Task Force on Prescription Drug Importation is also pre-
sented.4
A BRIEF HISTORY OF DRUG OVERSIGHT IN THE UNITED STATES
The policies and regulations of the current, relatively "closed"
U.S. drug distribution system maximize the safety and effectiveness of
the domestic drug supply. These policies and regulations also serve as
the model for systems around the world.
The discovery of penicillin in the 1930s signaled the start of the
modern era of drug research and development.' As more new drugs
1. Victoria Arocho, More Than 40% of Americans Using Prescription Drugs, USA
TODAY, Dec. 3, 2004, available at http//www.usatoday.com/news/health/2004-12-02-
medicated-america_x.htm; U.S. DEP'T OF HEALTH & HUMAN SERVS., HHS TASK FORCE ON
DRUG IMPORTATION, REPORT ON PREscRPnION DRUG IMPORTATION 37-38 (2004), available at
http://www.hhs.gov/importtaskforce/Reportl220.pdf [hereinafter HHS TASK FORCE].
2. HHS TASKFORCE, supra note 1.
3. Id.
4. Id.
5. Id.
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emerged, Congress recognized the need for an oversight program to
ensure proper testing and manufacturing practices. As such, Congress
passed the Federal Food, Drug, and Cosmetic (FD&C) Act in 1938.6
The FD&C Act and its amendments in 1962 require that the U.S. Food
and Drug Administration (FDA) approve all new drugs for safety and
efficacy before marketing 7 and limit the types of drugs that can be im-
ported into the United States.8
In 1987, Congress passed the Prescription Drug Marketing Act
(PDMA) to address concerns that counterfeit, substandard, and inef-
fective drugs were making their way into the U.S. drug distribution
system.9 Importantly, PDMA also added the "American Goods Re-
turned" provision to the FD&C Act, which prohibits drug reimporta-
tion into the United States by any entity other than the manufacturer of
the drug. 10
Passed by Congress in 2003, the Medicare Prescription Drug, Im-
provement, and Modernization Act (MMA) provides the first-ever
prescription drug benefit for seniors and individuals with disabilities.
Provisions in MMA also allow the importation of certain FDA-
approved prescription drug products into the United States from Can-
ada, contingent upon certification from the Secretary of HHS that im-
plementation of the new policy poses no added risk to public health
and safety and results in a significant reduction in the cost of drugs to
the American consumer."1
Additionally, MMA mandated the Secretary of HHS to conduct a
comprehensive study of issues related to drug importation. In Febru-
ary 2004, Secretary Tommy G. Thompson appointed Richard H. Car-
mona, Surgeon General of the U.S. Public Health Service, to lead a
task force to conduct the requisite study, the findings of which were
published in December 2004.
6. See, e.g., John P. Swann, History of the FDA, in THE HISTORICAL GUIDE TO
AMERICAN GOVERNMENT (George Kurian ed., Oxford Univ. Press 1998), available at
http://www.fda.gov/oc/history/historyoffda/fulItext.htmi.
7. Id.
8. Id.; HHS TASK FORCE, supra note 1; FDA, IMPORTATION OF PRESCRIPTION
MEDICINES/DRUGS, http://www.fda.gov/ora/import/traveleralert.htm (last visited Aug. 17,
2005).
9. HHS TASK FORCE, supra note 1.
10. Id.; Joint Hearing of the Subcomm. on Health Care & Subcomm. on Int'l Trade of
the Comm. on Fin., 108th Cong. (2004) [hereinafter Joint Hearings] (statement of William K.
Hubbard, Associate Comm'r for Policy & Planning, FDA), available at
http://www.fda.gov/ola/2004/importeddrugs0427.htm.
11. HHS TASK FORCE, supra note 1.
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SCOPE AND NATURE OF THE DRUG IMPORTATION PROBLEM
Although difficult to quantify, the number of prescription drug
products entering the United States each year is large and has in-
creased over time. Data from Intercontinental Marketing Services
Health (IMS) suggests that about "$1.1 billion in pharmaceuticals
were imported into the United States in 2003. ' ' 2 Most imported drugs
(e.g., inhalants, capsules, tablets, injectables, biologics, and controlled
substances) are not approved by the FDA for quality, safety, and effi-
cacy, and may not meet the standards of products available in Ameri-
can pharmacies.
At the present time, two categories of imported drugs are consid-
ered legal: those that are manufactured in an FDA-inspected facility
and adhere to FDA standards, and those that are manufactured in the
United States, sent abroad, and subsequently reimported to the United
States by the manufacturer under standards set forth in the FD&C
Act.13 The quality, safety, and efficacy of two other categories of im-
ported drugs cannot be verified: those produced in a foreign facility
that also produces the U.S.-approved version, and those produced in a
foreign facility that have not been inspected by the FDA. 14 The latter
category poses the greatest risk to consumers because adherence to
good manufacturing practices and the integrity of drug packaging, la-
beling, storage, and distribution cannot be verified.
Prescription drug products enter the United States through interna-
tional mail facilities, private courier hubs, ports, and express consign-
ment facilities, and pedestrian traffic across borders. 5 "Storefront
pharmacies," walk-in businesses that serve as the middlemen between
foreign (primarily Canadian) drugstores and consumers, surfaced in
early 2004.16 The Internet has further facilitated long-distance drug
selling and purchasing.
12. Press Release, FDA, FDA Partners with States to Warn Consumers that "Looks Can
Be Deceiving" (Apr. 13, 2004), available at http://www.fda.govlbbs/topics/news/2004/
NEW0053.html.
13. HHS TASK FORCE, supra note 1.
14. Id.
15. Id.
16. Id.
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Pedestrian Traffic
In 2003, about twelve million prescriptions were sold by Canadian
pharmacies to American consumers; cross-border prescription drug
sales totaled $695 million.17 Organized travel to Canada-most com-
monly, bus trips by senior citizen groups-has seemingly increased
since 2000, and some of the trips have been organized by high-profile
political figures (e.g., members of Congress and governors) to draw
attention to the difference in price between U.S. and Canadian drugs. 8
Although studies have not documented the types of drugs being im-
ported in this manner, it is believed that most of the drugs are those
used for chronic conditions, such as diabetes, high cholesterol, hyper-
tension, and arthritis. 19
In 2000, the FDA's Southwest Import District and other agencies
conducted a survey at eight points of entry along the Mexican border
to study the types of drugs being brought into the United States by pe-
destrians. After interviewing more than 600 individuals during a four-
hour period at border entry points in Texas, Arizona, and California,
the data showed that most of the drugs were pain relievers or antibiot-
ics. Only 63% of the pedestrians had prescriptions. Of the pedestri-
ans with prescriptions, 59% were U.S. prescriptions and 41% were
Mexican prescriptions. Although many of the products were foreign
versions of FDA-approved drugs, some of the products "bore no re-
semblance whatsoever to any FDA-approved product in the United
States." 0
The findings of a second four-hour survey conducted by several
U.S. government agencies at seven entry points along the United
States and Mexico border in 2001 showed that 586 individuals trans-
ported 1120 drug products across the border.21 Only 56% of individu-
als had a prescription for the purchased drugs; 61% of which were
U.S. prescriptions and 39% of which were Mexican prescriptions. 22
As in the 2000 survey, many of the products were foreign versions of
FDA-approved drugs, and others were not approved for American
sale.
17. Id.
18. Id.
19. Id.
20. Id. at 16.
21. Id. at 37-38.
22. Id.
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Storefront Phannacies
Storefront pharmacies in the United States enable consumers to
receive drugs from foreign drugstores without traveling to the source
country. The illegal procedure is easily executed: 3 an individual
"walks in" to a storefront pharmacy, presents a prescription, and pays
the price specified for the drug. The prescription is then faxed to the
foreign pharmacy. The unapproved drug product is mailed directly to
the consumer, and the two "businesses" split the profits from the sale.
Many states have taken legal action against storefront pharmacies
for violating laws prohibiting drug sales without proper licensing. In a
major case against Rx Depot, a storefront pharmacy operating in vari-
ous locations throughout the United States, a judge ruled that "drugs
sold in this manner were both illegal and potentially unsafe."24 None-
theless, many such establishments continue to offer their services to
consumers seeking less expensive drug products.
The Internet
According to studies conducted in 2000 by the FDA Office of
Criminal Investigations and the General Accounting Office, about 300
to 400 Internet sites-50% of which are located outside of the United
States-sell prescription drug products directly to consumers.25 In the
United States, state boards of pharmacy have the primary responsibil-
ity of regulating online pharmacies, and agencies such as the FDA and
Drug Enforcement Administration provide federal oversight. 6 The
same regulations that apply to traditional pharmacies usually apply to
online pharmacies. An online pharmacy can also voluntarily apply for
Verified Internet Pharmacy Practice Sites (VIPPS) certification, a
program established in 1999 by the National Association of Boards of
Pharmacy to address legitimacy concerns.27
Many properly licensed and certified online pharmacies provide
notable advantages to consumers, including the convenience of order-
ing and receiving products without leaving home, the ease of compari-
23. Id.
24. Id. at 16.
25. Id.
26. See NAT'L ASS'N OF BOARDS OF PHARMACY, VIPPS CRITERIA: LICENSURE AND
POLICY MAINTENANCE (2005), available at http://www.nabp.net/vipps/consumer/criteria.asp
[hereinafter VIPPS CRITERIA].
27. Id.; Michelle Meadows, Imported Drugs Raise Safety Concerns, FDA CONSUMER,
Sept.-Oct. 2002, available a http://www.fda.gov/fdac/features/2002/502_import.html.
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son shopping, and increased privacy. 2 Yet others, both domestic and
foreign, sell unapproved drug products based solely on an online ques-
tionnaire or without offering the services of a pharmacist. 29 Further-
more, some online pharmacies provide no contact information, such as
a phone number or physical address; thus a consumer has no way of
determining the source or quality of the product being purchased.3" Of
note is the fact that Canadian pharmacy Internet sites "are often not
located in Canada or even regulated by the Canadian government" and
evidence shows that "Americans are not always getting the same
drugs as Canadian citizens when purchasing drugs from Canadian
Internet sites or sites purporting to be Canadian."31
RISKS TO PATIENT SAFETY
Whether purchased online, from a storefront pharmacy, or during
travel to another country, foreign prescription drugs pose risks to pa-
tient safety; the most serious of which include counterfeit potential,
quality assurance concerns, presence of untested ingredients, and is-
sues related to risk management and unsupervised use, labeling, lan-
guage, and lack of information.3 2 Products considered particularly
risky for importation include injectable drugs, biological products,
controlled substances, drugs inhaled during surgery, drugs with spe-
cific post marketing risk monitoring guidelines, drugs that require re-
frigeration or that must be kept frozen, and drugs with a high potential
for counterfeiting on a global scale.33
Some imported drugs may be counterfeit versions of the genuine
product and contain unsafe (highly potent) or ineffective (subpotent or
expired) substances. Highly potent drugs have the potential to induce
adverse events, some of which could be life threatening. Subpotent or
outdated drugs would likely not produce the desired benefit, yet a pa-
tient would be unaware that the source of treatment failure was the
drug itself. Furthermore, because counterfeit drugs often bear the
28. VIPPS CRITERIA, supra note 26.
29. Id.
30. Id.
31. HHS TASK FORCE, supra note 1, at 17.
32. See Meadows, supra note 27; FDA, FDA Crackdown on Illegal Products, FDA
CONSUMER, Mar.-Apr. 2004, available at http://www.fda.gov/fdaclfeatures/2004/
204illegal.html [hereinafter FDA Crackdown]; CTR. FOR DRUG EVALUATION & RESEARCH,
FDA, LOOKS CAN BE DECEIVING: DON'T RISK YOUR HEALTH (2004), available at
http://www.fda.gov/cder/consumeninfo/border.htm [hereinafter LOOKS CAN BE DECEIVING]
33. HHS TASK FORCE, supra note 1.
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name of an FDA-approved product, consumers may be tricked into
believing that a drug has been manufactured and regulated by U.S.
standards.
The quality assurance procedures of drugs produced in foreign
countries cannot be verified; thus consumers of such products have no
guarantees that good manufacturing practices have been met or that
packaging, handling, storage, and distribution procedures have been
adequate to avoid deterioration, contamination, or degradation. Im-
ported drugs could contain ingredients that have not been tested and
confirmed safe and effective by U.S. standards, even though such in-
gredients may be legitimate and legal in the country of production.
Furthermore, if problems arise with an imported product, consumers
have little recourse with foreign operators.
Drugs purchased from foreign sources may be labeled in a lan-
guage other than English, thereby making critical information about
dosage and adverse effects inaccessible. Instructions may be lacking
as to how to deal with emergent situations or false claims may be
made about the drug's safety and efficacy or its intended or specific
use. Consumers purchasing imported products may not have access to
physician supervision, even though regular check-ups and follow-up
examinations are important risk management measures while taking
certain drugs.
IMPORT BLITZ EXAMS HELP TO QUANTIFY
THE DRUG IMPORTATION PROBLEM
Import blitz exams (i.e., snap inspections) conducted by the FDA
and U.S. Customs and Border Protection in July and August 2003
showed that 88% of the 1153 packages examined at four international
mail facilities contained unapproved drugs. 34 The blitzes were con-
ducted over a three-day period in Miami, New York (JFK airport),
San Francisco, and Carson, California. The drugs entered the United
States from all over the world, including 16% from Canada, 14% from
India, 14% from Thailand, and 8% from the Philippines.35
A second series of import blitz exams performed by the same
agencies in November 2003 at international mail facilities in Chicago,
Dallas, Buffalo, and Seattle, and private courier hubs in Memphis and
Cincinnati revealed that 69% of the 3375 packages examined con-
34. Joint Hearing, supra note 10.
35. Id.
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tained unapproved products, including recalled drugs, drugs requiring
special storage, and drugs containing controlled substances. 36 Eighty
percent of the packages entered the United States from Canada, 16%
were from Mexico, and the remaining packages came from the United
Kingdom, the Netherlands, Japan, Taiwan, and Thailand.37
The following list includes examples of the types of products
found during the blitz exams:38
* Drugs improperly packaged in envelopes, sandwich bags,
and tissue paper. Some drugs were "broken" or "crushed;"
* More than twenty-five different controlled substances
(e.g., anabolic steroids, diazepam, codeine, alprazolam,
lorazepam, and clonazepam), which were referred to the
Drug Enforcement Administration;
* Drugs with the potential for harmful interactions with
other drugs, including unapproved versions of sildenafil
(Viagra) from the United Kingdom, Philippines, India, and
Japan, as well as unapproved versions of simvastatin (Zo-
cor) from Canada;
" Animal drugs not approved for use in humans, including
clenbuterol, a drug used to treat airway diseases in horses.
Of note is that this drug is known to be abused by body-
builders and is banned by the International Olympic
Committee;
" Drugs inadequately labeled for safe use or labeled in a
language other than English;
* Drugs requiring risk management (screening and monitor-
ing) programs, such as unapproved versions of the choles-
terol drugs atorvastatin (Lipitor) from the Philippines,
United Kingdom, Canada, Ireland, Thailand, Japan, Ar-
gentina, New Zealand, and Brazil, and pravastatin (Prava-
chol) from Canada;
* Drugs requiring careful dosing, including unapproved ver-
sions of phenytoin (Dilantin) from the Philippines,
levothyroxine (Synthroid) from Canada, and metformin
(Glucophage) from the Philippines and Canada;
" Drugs withdrawn from the market, including the unap-
proved Mexican drug Buscapina, which seemed to be
36. Id.
37. Id.
38. Id.; FDA Crackdown, supra note 32.
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dipyrone (Dimethone), a fever and pain medication re-
moved from the U.S. market in 1977;
" Unapproved drugs like human growth hormone and the
immunosuppressant alti-azathioprine;
" Unapproved versions of FDA-approved drugs, such as
Roaccutane, an unapproved version of the acne drug isot-
retinoin (Accutane) from Thailand, and taro-warfarin, an
unapproved version of the anticlotting agent warfarin from
Canada;
* Potentially recalled drugs-for example, the asthma treat-
ment drugs Serevent Diskus and Flovent Diskus from
Canada.
ALTERNATIVES TO THE IMPORTATION OF PRESCRIPTION
DRUG PRODUCTS
The current relatively closed system of legal prescription drug dis-
tribution provides the American consumer with several layers of pro-
tection against receiving unsafe, ineffective, and poor quality drugs.
Revamping the system to include legalized drug importation would
likely result in an increased risk of substandard and counterfeit prod-
ucts entering the distribution chain. The implementation of a com-
mercial importation program might be possible, but "new legal au-
thorities, substantial additional resources, and significant restrictions
on the type of drugs that could be imported" would be required. 9 In
the end, such measures might increase, not decrease, the cost of drugs.
A personal importation program would create "numerous vulnerabili-
ties in the drug distribution system" and put American consumers at
risk.4°
Current efforts to find and implement alternatives to imported
drugs seem promising. The FDA has been active in helping to accel-
erate access to generic drugs and to educate consumers on their use.
U.S. generics-which account for about one-half of all prescrip-
tions-generally cost 50% to 70% less than their brand name counter-
parts.4 1 Of interest, a study conducted in 2002 shows that six of seven
widely used U.S. generic drugs were less expensive than their brand
39. HHSTASKFORCE, supra note 1, at 23.
40. Id. at 58.
41. OFFICE OF PLANNING, FDA, FDA WHITE PAPER: GENERIC DRUG PRICES IN THE U.S.
ARE LOWER THAN DRUG PRICES IN CANADA (2003), available at http://www.fda.gov/
oc/whitepapers/drugprices.html.
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name counterparts in Canada and five of the U.S. generics were less
expensive than Canadian generics.
4 2
The FDA recently initiated the "Looks Can Be Deceiving" public
information campaign to educate American consumers about the dan-
gers of buying unapproved foreign drugs.43 Educational materials,
such as posters, tabletop displays in pharmacies, and prescription bag
inserts, use straightforward language to caution customers that im-
ported drugs may be of substandard quality, outdated, or counterfeit.'
To more effectively distribute these materials, the FDA has begun
partnering with state pharmacist associations and drugstore chains.45
The FDA also continues to explore ways to lower drug development
and manufacturing costs and anticipates that the new Medicare pre-
scription drug benefit will further assist seniors in purchasing afford-
able and safe medications.'
CONCLUSIONS
The standards of the FD&C Act regulate the way in which pre-
scription drugs are manufactured, packaged, labeled, stored, and
shipped. However, the safety and efficacy of products imported to the
United States cannot be ensured because of noncompliance with the
FD&C standards. The position of the author of this essay, that im-
ported prescription drugs pose serious risks to patient safety and that a
legal importation program would be difficult and costly to implement,
is supported by the following key findings of the HHS Task Force on
Prescription Drug Importation: 47
" The current system of drug regulation in the United States
has been very effective in protecting public safety and
should be modified only with great care;
* Significant risks are associated with the current manner of
drug importation;
* Safety hazards from "individual" importation are difficult
to address and prevent;
42. Id.
43. LOOKS CAN BE DECEIVING, supra note 32.
44. Id.
45. Id.
46. See Joint Hearing, supra note 10; LOOKS CAN BE DECEIVING, supra note 32.
47. HHS TASK FORCE, supra note 1.
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" The overall national savings from legalized commercial
importation would be a small percentage of total drug
spending. Furthermore, developing such a program would
be costly;
" The belief that most imported drugs are less expensive
than American drugs is not generally true;
* Legalized importation would likely result in lowered re-
search and development incentives;
* Legalized importation would likely result in numerous
constitutional issues regarding intellectual property rights;
and
* Legalized importation would likely result in liability con-
cerns for consumers, manufacturers, distributors, pharma-
cies, and other entities.
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